Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2022-08-25 Annual Report
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
FY22 Full Year Accounts 56 pages 4.3MB
Annual Report Classification · 95% confidence The document is titled 'APPENDIX 4E Preliminary Final Report' and contains detailed financial results for the year ended 30 June 2022, including revenue, net loss, segment performance, cash flow, and balance sheet data. It references compliance with ASX listing rules and includes a comprehensive review of operations and financial performance. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes audited financial report references and detailed financial metrics, which are typical of an annual report. The presence of a full year period, detailed financial statements, and operational review confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2022-08-25 English
MVP Announces FY22 Full Year Results 2 pages 759.9KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 26 August 2022 titled 'FY22 FULL YEAR RESULTS'. It contains detailed financial figures for the full fiscal year ended 30 June 2022, including revenue, EBIT, and NPAT, as well as commentary on business performance, strategic focus, leadership changes, and outlook for FY23. The presence of comprehensive financial data and management commentary indicates this is a full annual financial report rather than a brief earnings release or a simple announcement. The document length is 4729 characters, which is sufficient to include substantive financial data and analysis. Therefore, this document fits the definition of an Annual Report (10-K equivalent) rather than an Earnings Release or Report Publication Announcement. Hence, the correct classification is Annual Report (10-K). FY 2022
2022-08-25 English
FY222 Full Year Results Investor Presentation 21 pages 1.7MB
Annual Report Classification · 95% confidence The document is a detailed presentation of the full year financial results for FY22 of Medical Developments International Limited. It includes comprehensive financial data such as revenue, EBIT, NPAT, cash position, segment performance, and strategic outlook. The document also discusses forward-looking statements, company overview, financial highlights, and growth strategies. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis rather than just an announcement or summary. The content aligns with a full annual financial report rather than a brief earnings release or investor presentation. Therefore, the document fits the definition of an Annual Report (10-K equivalent) or a full year financial report. Given the Australian context and the detailed financial and strategic information, the best classification is Annual Report (10-K). FY 2022
2022-08-25 English
Supplementary Prospectus 2 pages 73.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'SUPPLEMENTARY PROSPECTUS' and refers to supplementing a previously issued Prospectus dated 4 August 2022. It discusses details about an Entitlement Offer, proposed use of funds, capital raising, and related party arrangements. The document is lodged with ASIC and references the Corporations Act 2001. The content focuses on capital raising activities and updates to the original prospectus, which is typical of a capital/financing update. The document length is 4020 characters, which is relatively short but contains substantive information about the capital raising and related financial details, not merely an announcement or a link to a report. Therefore, it is not a report publication announcement or a regulatory filing. It is not an annual or interim report, nor an earnings release or management report. The best fitting category is Capital/Financing Update (CAP).
2022-08-24 English
Advance Notice MVP FY22 Full Year Results Release 1
Report Publication Announcement Classification · 95% confidence The document is an ASX announcement dated 23 August 2022, providing advance notice that Medical Developments International will announce its FY22 full year results on 26 August 2022. It includes details about a briefing to be held on the announcement date and contact information. The document does not contain any actual financial data or results, nor does it include the full annual report or earnings release. It is a short notice informing investors about the upcoming release of the full year results and the briefing. According to the 'MENU VS MEAL' rule, such a short announcement that states when results will be announced and briefing details is classified as a Report Publication Announcement (RPA), not the report itself (10-K or ER). Therefore, the correct classification is RPA with high confidence.
2022-08-22 English
Change in substantial holding 4 pages 210.7KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Corporations Act 2001 Section 671B Notice of Change of Interests of Substantial Holder'. It details changes in voting power and shareholdings of a substantial holder (FIL Limited) in Medical Developments International Limited. The content includes dates, number of shares bought and sold, and relevant interests, which are typical for notifications of major shareholding changes. There is no financial performance data, management discussion, or report publication. The document is regulatory in nature, specifically about shareholding notifications. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length (6979 characters) supports it being a full notification rather than a brief announcement or certification.
2022-08-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.